Methyl-CCNU (NSC-95441) in advanced colorectal carcinoma after failure of 5-fluorouracil (NSC-19893) therapy.
Twenty-seven patients with advanced colorectal carcinoma who had earlier failed to respond to 5-fluorouracil (5-FU) were given methyl-CCNU. Of the 21 patients who received methyl-CCNU alone, two (9.5%) responded partially with a mean duration of 28 weeks. Of the six patients who received methyl-CCNU and beta-TGdR, three had a partial response. There were no complete responses in either group. Response was not related to performance status, site of metastasis, or previous response to 5-FU treatment. It seems that the addition of beta-TGdR to methyl-CCNU might give better results after failure to previous 5-FU treatment. Hematologic toxicity was noted in 33% of the patients and gastrointestinal toxicity in 25%.
D000230:Adenocarcinoma / Q000188:drug therapy; D000328:Adult; D000368:Aged; D001791:Blood Platelet Disorders / Q000139:chemically induced; D002986:Clinical Trials as Topic; D003110:Colonic Neoplasms / Q000188:drug therapy*; D004341:Drug Evaluation; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use*; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008130:Lomustine / Q000627:therapeutic use* / Q000633:toxicity; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009607:Nitrosourea Compounds / Q000627:therapeutic use*; D012004:Rectal Neoplasms / Q000188:drug therapy*
D009607:Nitrosourea Compounds; D008130:Lomustine; D005472:Fluorouracil